{"analyses":[{"ciLowerLimit":"0.30","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.60","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.42","statisticalMethod":"Stratified Log Rank Test"}],"classes":[{"categories":[{"measurements":[{"comment":"NA due to insufficient number of events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"9.33","upperLimit":"12.09","value":"10.84"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"210"},{"groupId":"OG001","value":"208"}],"units":"Participants"}],"description":"OS is defined as the time between the date of randomization and the date of death or the last date the participant was known to be alive.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received nivolumab, 3 mg/kg, solution administered Intravenously (IV) every 2 weeks with placebo-matching dacarbazine solution administered IV every 3 weeks, until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion","id":"OG000","title":"Nivolumab, 3 mg/kg + Placebo-matching Dacarbazine"},{"description":"Participants received dacarbazine 1000 mg/m\\^2, solution administered IV every 3 weeks with placebo-matching nivolumab solution administered IV every 2 weeks until disease progression, discontinuation due to toxicity, withdrawal of consent, or study completion","id":"OG001","title":"Dacarbazine, 1000 mg/m^2 + Placebo-matching Nivolumab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of death. For those without documentation of death, to the last date the participant was known to be alive, assessed up to 17 months.","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}